Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16973611 | 0.80 | ALDH1A1 (0.40) | TMEM97SIGMAR1KCNH2 | |
| SCHEMBL4910377 | 0.79 | PNMT (0.58) | TMEM97SIGMAR1PNMTTAAR1KCNH2 | |
| SCHEMBL4986765 | 0.77 | PNMT (0.42) | TMEM97SIGMAR1PNMTTAAR1LIPG | |
| SCHEMBL661213 | 0.76 | TSHR (0.51) | TSHR | |
| SCHEMBL4983954 | 0.75 | PNMT (0.46) | TMEM97SIGMAR1PNMTTAAR1LIPG | |
| SCHEMBL10859086 | 0.75 | PNMT (0.67) | TMEM97SIGMAR1PNMTTAAR1KCNH2 | |
| SCHEMBL14731704 | 0.75 | PNMT (0.67) | TMEM97SIGMAR1PNMTTAAR1KCNH2 | |
| SCHEMBL3393678 | 0.75 | PYGL (0.57) | SIGMAR1PNMTTAAR1TSHRPYGL | |
| SCHEMBL7089879 | 0.75 | ALDH1A1 (0.43) | — | |
| SCHEMBL12436727 | 0.75 | SIGMAR1 (0.58) | TMEM97SIGMAR1PNMTTAAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | TMEM97 3926/4885SIGMAR1 4036/4885PNMT 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.